Quantcast

Latest Intravenous immunoglobulin Stories

2008-09-23 12:00:13

A study of a treatment for chronic inflammatory demyelinating neuropathy (CIDP) suggests that 50 percent of the patients who responded to treatment with Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) required two treatments before they first exhibited improvements on a standard disability measurement scale, according to data presented at the American Neurological Association meeting in Salt Lake City, Utah. The study authors concluded that "further...

2008-09-15 09:00:11

The FDA has approved Talecris Biotherapeutics's Gamunex, an immune globulin product for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The FDA designated Gamunex as an orphan drug to treat chronic inflammatory demyelinating polyneuropathy (CIDP). The FDA based its approval of Gamunex on clinical trials that showed Gamunex was effective at improving...

2008-09-15 09:00:11

Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted approval for Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a debilitating neurological disorder that results in muscle weakness and fatigue, which can lead to severe impairment of motor skills. Through its approval, Gamunex is the only therapy of any kind with an...

2008-09-05 09:00:08

Biotech company Pharming Group has announced that the FDA has authorized a clinical study with recombinant human C1 inhibitor for the treatment of antibody-mediated rejection in kidney transplantation. Hans Sollinger of the University of Wisconsin, Madison will conduct the clinical trial with recombinant human C1 inhibitor (rhC1INH) under an investigator IND from the FDA. Recombinant human C1 inhibitor is a key inhibitor of the classical complement system. In the planned study, rhC1INH...

2008-08-05 09:00:13

Brief Report Lymphocytic choriomeningitis virus (LCMV) is a rodent-borne arenavirus found worldwide. House mice (Mus musculus) are the natural reservoir, but LCMV also can infect other wild, pet, and laboratory rodents (e.g., rats, mice, guinea pigs, and hamsters). Humans can be infected through exposure to rodent excreta. Person-to-person transmission has occurred only through maternal-fetal transmission and solid organ transplantation (1-3). LCMV infection in humans can be asymptomatic or...

2008-07-31 12:00:23

U.S. medical scientists say a drug commonly prescribed to treat immunodeficiencies has shown promise as a treatment for Alzheimer's disease. Researchers at NewYork-Presbyterian Hospital and the Weill Cornell Medical Center announced the nine-month interim results of an ongoing Phase II double-blind, placebo-controlled clinical trial of gammagard intravenous immunoglobulin, or IGIV. Those results show significantly better global outcomes, cognitive performance and daily functioning in...

2008-07-31 09:01:26

LINCOLN, Neb., July 31 /PRNewswire/ -- Today, Grifols Biomat USA celebrates the grand opening of a new plasma donor center in Lincoln, Nebraska. The Lincoln center located on 2002 N Street is one of 60 Biomat USA center to be opened in the United States and the first in Nebraska. The plasma donated at the Lincoln center is then used by Biomat USA's parent company Grifols to produce life-saving medicines. Plasma is part of the blood that contains proteins and antibodies that are needed...

2008-07-30 18:00:54

CHICAGO, July 30 /PRNewswire-USNewswire/ -- Results from clinical trials of three potential Alzheimer's therapies raise hope for new and better treatments of the disease, according to data reported today at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD 2008) in Chicago. A related study showed that taking antidementia drugs appears to have a positive impact on extending lifespan in those with Alzheimer's. These reports included: Eighteen-month...

2008-07-30 18:00:22

To: NATIONAL EDITORS Contact: Alzheimers Association media line: +1-312-335-4078, media@alz.org; ICAD 2008 press room, July 27-31: +1-312-949-3253 - Plus, Taking Antidementia Drugs Extends Lifespan Three Years in Alzheimers - CHICAGO, July 30 /PRNewswire-USNewswire/ -- Results from clinical trials of three potential Alzheimers therapies raise hope for new and better treatments of the disease, according to data reported today at the 2008 Alzheimers Association International Conference...

2008-07-21 12:00:20

HOBOKEN, N.J. and FRISCO, Texas, July 21 /PRNewswire/ -- Octapharma USA, the largest privately owned, plasma fractionation company in the world, and ASD Healthcare, a part of AmerisourceBergen Corp., one of the world's largest pharmaceutical services companies, will jointly serve as the national title sponsors of the 2008 A-T Cure Tour. The national series of marathons and races benefits the A-T Children's Project, a non-profit organization focused on finding a cure or life-improving...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related